regulatory status comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
==== 2.B Nonribosomally synthesized porters ==== 2.B.1 The Valinomycin Carrier Family 2.B.2 The Monensin Family 2.B.3 The Nigericin Family 2.B.4 The Macrotetrolide Antibiotic (MA) Family 2.B.5 The Macrocyclic Polyether (MP) Family 2.B.6 The Ionomycin Family 2.B.7 The Transmembrane α-helical Peptide Phospholipid Translocation (TMP-PLT) Family 2.B.8 The Bafilomycin A1 (Bafilomycin) Family 2.B.9 The Cell Penetrating Peptide (CPP) Functional Family 2.B.10 The Synthetic CPP, Transportan Family 2.B.11 The Calcimycin or A23187 Carrier-type Ionophore Family 2.B.12 The Salinomycin Family 2.B.13 The Tetrapyrrolic Macrocyclic Anion Antiporter (TPMC-AA) Family 2.B.14 The Lasalocid A or X-537A Ionophore (Lasalocid) Family 2.B.15 The Tris-thiourea Tripodal-based Chloride Carrier (TTT-CC) Family 2.B.16 The Halogen-bond-containing Compound Anion Carrier (HCAC) Family 2.B.17 The Isophthalaminde Derivative H+:Cl− Co-transporter (IDC) Family 2.B.18 The Pyridine-2,6-Dicarboxamine Derivative (PDCA) H+:Cl− Co-transporter Family 2.B.19 The Calix(4)pyrrole Derivative (C4P) Family 2.B.20 The Prodigiosin (Prodigiosin) Chloride/Bicarbonate Exchanger Family 2.B.21 The ortho-Phenylenediamine-bis-Urea Derivative Anion Transporter (oPDA-U) Family 2.B.22 The Imidazolium-functionalized Anion Transporter (IAT) Family 2.B.23 The Homotetrameric Transmembrane Zn2+/Co2+:Proton Synthetic Antiporter, Rocker (Rocker) Family 2.B.24 The 2,6-Bis(benzimidazol-2-yl)pyridine Anion Carrier (BBP-AC) Family 2.B.25 The Peptide-mediated Lipid Flip-Flop (PLFF) Family 2.B.26 The Bis(imidazolyl)-functionalized Bis(Choloyl) Conjugate (BIBCC) Family 2.B.27 The Tris-Urea Anion Transporter Family 2.B.29 The Anionophoric Marine Alkaloid Tambjamine Family
Naive T cells pass through the process of functional avidity maturation with no change in affinity. It is based on the fact that effector and memory (antigen-experienced) T cell are less dependent on costimulatory signals and higher antigen concentration than naive T cell.
Lithium toxicity, which is also called "lithium overdose" or "lithium poisoning", is the condition of having too much lithium in the blood. This condition also happens in persons who are taking lithium in which the lithium levels are affected by drug interactions in the body. Lithium toxicity occurs at levels above 1.5 mmol/L. Lithium levels above 2.0 mmol/L can lead to disorientation, renal failure, seizures, and coma. Above 2.0 mmol/L, acute renal failure can occur, and kidney dialysis may be used. In the elderly, signs of toxicity can occur at half the levels of younger patients. In acute toxicity, people have primarily gastrointestinal symptoms such as vomiting and diarrhea, which may result in volume depletion. During acute toxicity, lithium distributes later into the central nervous system resulting in mild neurological symptoms, such as dizziness. In chronic toxicity, people have primarily neurological symptoms which include nystagmus, tremor, hyperreflexia, ataxia, and change in mental status. During chronic toxicity, the gastrointestinal symptoms seen in acute toxicity are less prominent. The symptoms are often vague and nonspecific. If the lithium toxicity is mild or moderate, lithium dosage is reduced or stopped entirely. If the toxicity is severe, lithium may need to be removed from the body.
Sources: en.wikipedia.org
Fever or pyrexia in humans is a symptom of an anti-infection defense mechanism that appears with body temperature exceeding the normal range caused by an increase in the body's temperature set point in the hypothalamus. There is no single agreed-upon upper limit for normal temperature: sources use values ranging between 37.2 and 38.3 °C (99.0 and 100.9 °F) in humans. The increase in set-point triggers increased muscle contractions and causes a feeling of cold or chills. This results in greater heat production and efforts to conserve heat. When the set-point temperature returns to normal, a person feels hot, becomes flushed, and may begin to sweat. Rarely a fever may trigger a febrile seizure, with this being more common in young children. Fevers do not typically go higher than 41 to 42 °C (106 to 108 °F). A fever can be caused by many medical conditions ranging from non-serious to life-threatening. This includes viral, bacterial, and parasitic infections—such as influenza, the common cold, meningitis, urinary tract infections, appendicitis, Lassa fever, COVID-19, and malaria. Non-infectious causes include vasculitis, deep vein thrombosis, connective tissue disease, side effects of medication or vaccination, and cancer. It differs from hyperthermia, in that hyperthermia is an increase in body temperature over the temperature set point, due to either too much heat production or not enough heat loss. Treatment to reduce fever is generally not required. Treatment of associated pain and inflammation, however, may be useful and help a person rest.
As of 2018, about a quarter of annual global greenhouse gas emissions is the carbon dioxide from burning petroleum (plus methane leaks from the industry). Along with the burning of coal, petroleum combustion is the largest contributor to the increase in atmospheric CO2. Atmospheric CO2 has risen over the last 150 years to current levels of over 415 ppmv, from the 180–300 ppmv of the prior 800 thousand years. The rise in Arctic temperature has reduced the minimum Arctic ice pack to 4,320,000 km2 (1,670,000 sq mi), a loss of almost half since satellite measurements started in 1979. Ocean acidification is the increase in the acidity of the Earth's oceans caused by the uptake of CO2 from the atmosphere.The saturation state of calcium carbonate decreases with the uptake of carbon dioxide in the ocean. This increase in acidity inhibits all marine life—having a greater effect on smaller organisms as well as shelled organisms such as Pectinoidea.
== Substrates == So far, more than 150 proteins have been identified to be targets for CK1-mediated phosphorylation, at least in vitro. Phosphorylation of numerous substrates is enabled due to the existence of several consensus motifs, which can be recognized by CK1 isoforms.
Sources: en.wikipedia.org
=== Iodine === Iodine is used in chemistry as an indicator for starch. When starch is mixed with iodine in solution, an intensely dark blue colour develops, representing a starch/iodine complex. Starch is a substance common to most plant cells and so a weak iodine solution will stain starch present in the cells. Iodine is one component in the staining technique known as Gram staining, used in microbiology. Used as a mordant in Gram's staining, iodine enhances the entrance of the dye through the pores present in the cell wall/membrane. Lugol's solution or Lugol's iodine (IKI) is a brown solution that turns black in the presence of starches and can be used as a cell stain, making the cell nuclei more visible. Used with common vinegar (acetic acid), Lugol's solution is used to identify pre-cancerous and cancerous changes in cervical and vaginal tissues during "Pap smear" follow up examinations in preparation for biopsy. The acetic acid causes the abnormal cells to blanch white, while the normal tissues stain a mahogany brown from the iodine.
== Other uses == ck (digraph), a letter combination used in spelling C-K theory (concept-knowledge theory), in design CK (album), a 1988 album by Chaka Khan Civilinis kodeksas, the Code of Lithuania Cranbrook Kingswood, a school in the US
=== Debate over government intervention === A group of 599 venture capitalists, including Garry Tan and David O. Sacks, along with hedge fund manager Bill Ackman and California State Senator Scott Wiener, called for a government intervention to protect uninsured depositors. Representatives Ruben Gallego of Arizona and Eric Swalwell of California called for depositors to be made whole, while Representatives Ro Khanna and Brad Sherman of California called on the Treasury Department and FDIC to affirm that depositors would be protected so they could make payroll. Khanna pointed to the 1991 collapse of the Bank of New England as precedent for rescuing a regional bank. Representative Matt Gaetz of Florida and Republican presidential candidates Nikki Haley and Vivek Ramaswamy expressed opposition to any taxpayer-funded bailout of the bank. Ramaswamy suggested that the FDIC's deposit insurance limit be raised instead. San Jose Mayor Matt Mahan also called the $250,000 limit "arcane". Governor Newsom, Senator Kyrsten Sinema of Arizona, and Representative Anna Eshoo of California applauded the FDIC's announcement that it would protect depositors without affecting taxpayers via the Bank Term Funding Program. Mayor Mahan criticized the federal government's response to the bank's failure as slow and indicative of its misunderstanding of Silicon Valley startups' contribution to the national economy.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.